^
Association details:
| Biomarker: | EGFR exon 19 deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Conmana (icotinib) (EGFR inhibitor) + Ameile (aumolertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR-Mutant NSCLC with CNS Metastases: A Prospective Phase I/II Study
Published date:
08/08/2023
Excerpt:
This ongoing phase I/II study enrolled untreated EGFR (19 deletion or L858R) NSCLC patients with measurable CNS lesions…The confirmed ORR was 95.8% (23/24), DCR was 100% (24/24), iORR was 91.7% (22/24), iDCR was 100% (24/24), the CNS lesions shrinkage was observed in all patients with a median depth of tumor remission (DepOR) 53.6% (range 11.3%-77.4%)...Aumolertinib plus icotinib as first-line therapy have significant response rate and a manageable safety profile in EGFR-mutant NSCLC patients with CNS metastases.
Source:
Title:
EP08.02-067 - Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR Mutated Non-small Cell Lung Cancer with Brain Metastases
Published date:
07/12/2022
Excerpt:
This ongoing phase I/II study enrolled patients with stage IV EGFR-mutated (L858R or del19) NSCLC with brain metastases....The ORR of 6 patients in phase I was 100%....This is the first study to demonstrate that aumolertinib plus icotinib have preliminary efficacy and a tolerable safety profile in EGFR-mutated NSCLC patients with brain metastases.
